최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of pediatrics, v.53 no.4, 2010년, pp.538 - 547
김상정 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과) , 한동균 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과) , 백희조 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과) , 김동연 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과) , 남택근 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 방사선종양학과) , 황태주 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과) , 국훈 (전남대학교 의과대학 소아과학교실, 화순전남대학교병원 소아청소년과)
Purpose : This study aims to compare the outcome of total body irradiation (TBI)- or non-TBI-containing conditioning regimens for leukemia in children. Methods : We retrospectively evaluated 77 children conditioned with TBI (n=40) or non-TBI (n=37) regimens, transplanted at Chonnam National Universi...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
동종 조혈모세포 이식은 어떤 병의 치료 방법으로 쓰이는가? | 1968년 첫 번째 동종 조혈모세포이식(hematopoietic stem cell transplantation, HSCT)이 성공한 이래1) 동종 조혈모세포 이식은 다른 방법으로 완치가 불가능한 많은 혈액암, 골수기능부전질환, 면역결핍질환, 대사질환 등의 중요한 치료방법이 되었다2). | |
백혈병 환자에서 가장 중요한 치료 방법은 무엇인가? | 백혈병 환자에서 가장 중요한 치료방법은 항암화학요법으로 소아에서 가장 많은 급성림프구성백혈병(acute lymphoblastic leumemia, ALL)의 경우 항암화학요법 만으로 약 80% 환자에서 장기 생존이 가능하게 되었다3). 하지만 소아 급성골수성백혈병(acute myelogenous leukemia, AML)에서의 항암화학요법의 성적은 이에 미치지 못하여 약 50%의 환자가 생존한다4). | |
소아 백혈병 환자 중 장기 생존자의 경우 어떤 후유증을 겪는가? | 골수파괴형 전처치에 오래전부터 가장 흔히 사용되는 방법은 TBI로 cyclophosphamide (Cy) 혹은 cytosine arabinoside (ara-C) 등과 병합하여 이식을 시행할 때 소아 백혈병 환자의 약 43-50%에서 장기 생존을 가능하게 하였다8). 하지만 장기 생존자의 많게는 2/3에서 후기 합병증으로 성장 및 발달장애, 호르몬 이상, 신경학적 합병증, 불임 및 2차 암 등이 발생하여 삶의 질의 저하를 초래한다9). 따라서 TBI를 포함하지 않는 전처치도 개발되어 대표적인 알킬화제인 busulfan (Bu)과 다른 항암제를 고용량으로 병합하여 백혈병 환자의 전처치에 많이 사용하고 있다10, 11). |
Bach FH, Albertini RJ, Joo P, Anderson JL, BortinMM. Bonemarrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet 1968;2:1364-6.
Santos GW. Bone marrow transplantation in hematologic malignancies: current status. Cancer 1990;65:786-91.
Pui CH, Relling MV, Downing JR. Mechanism of disease, acute lymphoblastic leukemia. New Engl J Med 2004;350: 1535-48.
Ebb DH, Weinstein HJ. Diagnosis and treatment of childhood acute myelogenous leukemia. Pediatr Clin North Am 1997;44: 847-62.
Pui CH. Acute lymphoblastic leukemia. Pediatr Clin North Am 1997;44:831-46.
Grimwade D, Walker H, Oliver H, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
Granados E, Camara R, Madero L. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000;85:1060-7.
Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996;34:843-51.
Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 1984;68:711-7.
Davies SM, Ramsay NK, Klein JP. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340-7.
Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;82:2036-43.
Hartman AR, Williams S, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998;22:439-43.
Thomas E, Storb R, Clift RA. Bone marrow transplantation (first of two parts). N Engl J Med 1975;292:832-43.
Shulman HM, Sullivan KM, Weiden PL. Chronic graftversus- host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
The Korean Pediatric Society. Tables for age structure and growth pattern of Korean children and adolescence in 1998. Seoul; Kwangmoon Co, 1999:52-3.
Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:425-34.
Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-95
Creutzig U, Zimmermann M, Ritter J. Definition of a standard- risk group in children with AML. Br J Haematol 1999; 104:630-9.
Creutzig U, Ritter J, Zimmermann M. Improved treatment results in high risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study Acute Myeloid Leukemia-Berlin-Frankfurt- Munster 93. J Clin Oncol 2001;19:2705-13.
Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvement in outcome with chemotherapy alone in pediatric acute myeloid leukemia: result of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukemia Working Party. Br J Haematol 1998;101;130-40.
Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, et al. Induction chemotherapy with idarubicin plus N4-behenoyl- 1-beta-Darabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen - a prospective, cooperative multicenter study. Semin Hematol 1996;33:24-9
Ortega JJ, Diaz de Heredia C, Olive T. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologia 2003;88:290-9.
Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70:1382-8.
Heinzelmann F, Ottinger H, Muller CH, Allgaier S, Faul C, Bamberg M, et al. Total-body irradiation: role and indications results from the German registry for stem cell transplantation (DRST). Strahlenther Onkol 2006;182:222-30.
Ricardi U, Filippi AR, Biasin E, Ciammella P, Botticella A, Franco P, et al. Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. Strahlenther Onkol 2009;185:17-20.
Paivi M. Lahteenmaki, Chakrabarti S, Jacqueline M, Oakhill AH. Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease. Acta Oncologica 2004;43:196-203.
Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006;107:4961-7.
Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74.
Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Kabisch H, et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplantation 2001;27:349-54.
Cohen A, Rovelli A, Bakker B. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999;93:4109-15.
Park EY, Baek HJ, Han DK, Lee SJ, Cho YK, Kim YO, at al. Final height of children after stem cell transplantation. Korean J Hematol 2007:42:382-91.
Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M, et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2009;44: 303-8.
Patriarca F, Poletti V, Costabel U, Battista ML, Sperotto A, Medeot, et al. Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complications after allogeneic stem cell transplantation. Curr Stem Cell Res Ther 2009;4:161-7.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.